Date: 2015-04-14
Type of information: Establishment of a new subsidiary in the EU
Compound: Oncurious
Company: Thrombogenics (Belgium) VIB (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details: * On April 14, 2015, ThromboGenics, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announce the foundation of Oncurious NV, a new oncology company that will develop TB-403 for the treatment of pediatric brain tumors. VIB, a leading life sciences institute in Flanders, will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. In February 2013, a paper in Cell (Cell, 152, 1065-76, 2013) highlighted for the first time that PlGF plays a vital role in the brain and that its expression is required for the growth and spread of medulloblastoma. The paper was based on pre-clinical research conducted by Prof Rakesh Jain from the Massachusetts General Hospital at Harvard (Boston) and the team of Prof Peter Carmeliet from VIB/ KU Leuven.
Oncurious now plans to start a Phase I/IIa program with TB-403 in medulloblastoma patients. Enrollment of the first patient is expected for the end of 2015.
The favorable safety profile of TB-403 has already been demonstrated in clinical trials in patients with other diseases. BioInvent International AB will act as a co-development partner for this oncology project. ThromboGenics has retained the exclusive license for use of TB-403 in ophthalmic indications.
Financial terms:
Latest news:
